Anti-inflammatory pre-treatment and the resultant effects of interleukin-10: adjuncts to multi-therapeutical strategies

Abstract

With the advent of off-pump coronary bypass surgery, there is increasing demand for research in attenuating the deleterious effects of cardiopulmonary bypass (CPB). An improved understanding of the systemic inflammatory response syndrome (SIRS) has distinguished which areas of components have the most adverse effects and which are, in fact, anti-inflammatory. This classification of inflammatory components allows strategic treatment for those likely to cause the most clinically significant ‘effect’, suitably termed ‘effectors’. This article will identify current methods in treating ‘effectors’, as well as those components having anti-inflammatory effects.

This article selectively features certain inflammatory components by: (1) grouping them as being ‘mediators’ or ‘effectors’; (2) relating them to interleukin-10 (IL-10) and treatments potentiating anti-inflammatory effects; (3) summarizing their mechanisms of action; (4) recognizing the time periods during bypass exhibiting peak levels; and (5) investigating current treatment methods and identifying their significance to ‘effectors’.

A literature search in MEDLINE was performed, featuring articles of the English-language within the past 5 years.

Because of the characteristic of having interlinked multi-component cascades, it is evident that treating SIRS with a one-dimensional method would be inadequate. This article not only confirms the importance of a multi-factorial therapeutic approach, but also targets the inflammatory components having the highest potential for causing direct tissue damage, known as ‘effectors’. In addition, previous studies have found IL-10 to have ‘regulatory effects’ during periods of excessive pro-inflammatory stimuli. These findings may arouse new ideas in exploring the area of anti-inflammatory cytokines. In fact, future treatments may suggest a new classification featuring ‘mediators’, ‘effectors’, and ‘regulators’.

Get full access to this article

View all access options for this article.

References

Carney DE , Lutz CJ , Picone AL et al. Matrix metalloproteinase inhibitor prevents acute lung injury after cardiopulmonary bypass . Circulation 1999; 100: 400-406 .

Peek GJ , Firman RK. The inflammatory and coagulative response to prolonged extracorporeal membrane oxygenation . ASAIO J 1999; 45: 250-263 .

Sablotzki A , Dehne MG , Mann V et al. Plasma levels of selectins and interleukins in cardiovascular surgery using cardiopulmonary bypass . Thorac Cardiovasc Surg 1999; 47: 26-31 .

Moen O , Hogasen K , Fosse E et al. Attenuation of changes in leukocyte surface markers and complement activation with heparin-coated cardiopulmonary bypass . Ann Thorac Surg 1997; 63: 105-111 .

Ilton MK , Langton PE , Taylor ML et al. Differential expression of neutrophil adhesion molecules during coronary artery surgery with cardiopulmonary bypass . J Thorac Cardiovasc Surg 1999; 119: 930-937 .

Ashraf S , Tian Y , Cowan D , Entress A , Martin PG , Watterson KG. Release of proinflammatory cytokines during pediatric cardiopulmonary bypass: heparin-bonded versus nonbonded oxygenators . Ann Thorac Surg 1997; 64: 1790-1794 .

Horton SB , Butt WW , Mullaly RJ et al. IL-6 and IL-8 levels after cardiopulmonary bypass are not affected by surface coating . Ann Thorac Surg 1999; 69: 1751-1755 .

Baksaas ST , Videm V , Mollnes TE et al. Leucocyte filtration during cardiopulmonary bypass hardly changed leucocyte counts and did not influence myeloperoxidase, complement, cytokines or platelets . Perfusion 1998; 13: 429-436 .

Mihaljevic T , Tonz M , von Segesser LK et al. The Influence of leukocyte filtration during cardiopulmonary bypass on postoperative lung function. A clinical study . J Thorac Cardiovasc Surg 1995; 109: 1138-1145 .

10.

Gu YJ , deVries AJ , Boonstra PW , van Oeveren W. Leukocyte depletion results in improved lung function and reduced inflammatory response after cardiac surgery . J Thorac Cardiovasc Surg 1996; 112: 494-500 .

11.

Kawamura T , Inada K , Nara N , Wakusawa R , Endo S. Influence of methylprednisolone on cytokine balance during cardiac surgery . Crit Care Med 1999; 27: 545-548 .

12.

Tabardel Y , Duchateau J , Schmartz D et al. Corticosteroids increase blood interleukin-10 levels during cardiopulmonary bypass in men . Surgery 1996; 119: 76-80 .

13.

Harig F , Feyrer R , Mahmoud FO , Blum U , von der Emde J. Reducing the post-pump syndrome by using heparin-coated circuits, steroids, or aprotinin . Thorac Cardiovasc Surg 1999; 47: 111-118 .

14.

Hill GE , Diego RP , Stammers AH , Huffman SM , Pohorecki R. Aprotinin enhances the endogenous release of interleukin-10 after cardiac operations . Ann Thorac Surg 1998; 65: 66-69 .

15.

Tassani P , Richter JA , Barankay A et al.

Does high-dose methylprednisolone in aprotinin-treated patients attenuate the systemic inflammatory response during coronary artery bypass grafting procedures?

J Cardiothorac Vasc Anesth 1999; 13: 165-172 .